Trial for new epilepsy med

Posted by cathy5161 @cathy5161, 6 days ago

Shortly starting an open label clinical trial to evaluate a new epilepsy drug called vormatrigine, developed by Praxis Precison Meds. It's 14 weeks long, divided into extensive screening, and a number of visits with a great deal of assessments and procedures. Belive this is first phase, which I'm sure with no placebo, looking for side effects and adverse reactions to study drug. 50 or so participants, across the globe, who have focal onset or tonic-clonic seizures, all getting same dosage, are the first guinea pigs.
1. Anyone heard of this trial or study drug?
2. Anyone actually doing it?
3. Any other thoughts or comments?

Interested in more discussions like this? Go to the Epilepsy & Seizures Support Group.

cathy5161 | @cathy5161 | 2 days ago

In reply to @santosha "Hi @cathy5161 Today, I came across this article: Common genetic variants linked to drug-resistant epilepsy. @closetmonster93,..." + (show)

Thank you Chris. I will ask my neurologist her take on this.
Appreciate you passing it on.

cathy5161 | @cathy5161 | 2 days ago

In reply to @jamessr "Does anyone have a link on how to contact Praxis for participation eligibility? James" + (show)

Praxis uses contract nurses to do initial pre-screening. The main number I have for that is 866-812-2202. The trial I am in is called Radiance (PRAX-628-212.) It might be full but worth a call.

There are much larger studies to follow - these of the double blind placebo type i think these are labeled "Power".

Chris Gautier | @santosha | 2 days ago

In reply to @cathy5161 "Thank you Chris. I will ask my neurologist her take on this. Appreciate you passing it..." + (show)

My pleasure @cathy5161 !
I would appreciate if you can share your neurologist's view on that. I will be having an appointment with my immunologist and neurologist in June and will also ask them about it, sharing with you.
Chris (@santosha)